洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR2600131501】Effect of Aloe Vera- Peppermint compound gel in prevention bed injuries among ICU bedridden patients

基本信息
登记号

ChiCTR2600131501

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2026-09-03

临床申请受理号

/

靶点

/

适应症

Pressure injuries

试验通俗题目

Effect of Aloe Vera- Peppermint compound gel in prevention bed injuries among ICU bedridden patients

试验专业题目

Effectiveness of a Combined Aloe Vera–Peppermint Gel on Prevention Pressure Injuries among Intensive Care Unit Patients: A Randomized Controlled Trial

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

Bab Al-Muaadham-Baghdad-Iraq

联系人通讯地址

/

临床试验信息
试验目的

1. To evaluate the effectiveness of an Aloe Vera–Peppermint compound gel in the prevention of pressure injuries among ICU patients. 2. To examine the relationship between the use of Aloe Vera–Peppermint gel and the demographic characteristics of ICU patients in relation to pressure injury prevention.

试验分类
请登录查看
试验类型

随机平行对照

试验分期

其它

随机化

Patients were assigned to the two groups using simple random sampling method

盲法

Open-label

试验项目经费来源

Self-funded

试验范围

/

目标入组人数

19

实际入组人数

/

第一例入组时间

2026-04-10

试验终止时间

2027-04-15

是否属于一致性

/

入选标准

1.ICU patients aged 18 years or older. 2.Admission to the ICU without pressure injury according to the NPUAP scale on the first day of hospitalization. 3.Unconsciousness, being under sedation or assisted ventilation. 4.Patients that are at risk of moderate to severe PIs according to Braden scoring tool and scored less than 13–14. 5.No Diarrhea, serum Albumin level below 3.5 g/dl, no edema. 6.No limit of changes in body position with multiple injuries. 7.Family consent to participate in the study. 8.The patient has no history of autoimmune diseases, renal failure, or diabetes, does not use immunosuppressive medications, and has no evidence of vascular disease. 9.All patients receiving standardized care (repositioning and pressure-relieving mattress). 1.ICU patients aged 18 years or older.2.Admission to the ICU without pressure injury according to the NPUAP scale on the first day of hospitalization.3.Unconsciousness, being under sedation or assisted ventilation.4.Patients that are at risk of moderate to severe PIs according to Braden scoring tool and scored less than 13–14.5.No Diarrhea, serum Albumin level below 3.5 g/dl, no edema.6.No limit of changes in body position with multiple injuries.7.Family consent to participate in the study.8.The patient has no history of autoimmune diseases, renal failure, or diabetes, does not use immunosuppressive medications, and has no evidence of vascular disease.9.All patients receiving standardized care (repositioning and pressure-relieving mattress).;

排除标准

1.Family’s unwillingness for the patient to continue participation 2.Sensitivity to Aloe Vera-Peppermint Gel after use on a patient's forearm (area of 2 × 2 cm) and this area was evaluated for the presence of redness, swelling and warmth within 45 min. 3.Spinal cord injury cases 4.Death or patient transmission in less than 48 hrs. after admission to the ICU.;

研究者信息
研究负责人姓名
请登录查看
试验机构

University of Baghdad, College of Nursing

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

Bab Al-Muaadham-Baghdad-Iraq

联系人通讯地址

/

更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

389,122个
全球在研药物数
5,767个
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,632亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看